These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 37018987)

  • 21. Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir.
    Gammeltoft KA; Zhou Y; Ryberg LA; Pham LV; Binderup A; Hernandez CRD; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.
    Eng H; Dantonio AL; Kadar EP; Obach RS; Di L; Lin J; Patel NC; Boras B; Walker GS; Novak JJ; Kimoto E; Singh RSP; Kalgutkar AS
    Drug Metab Dispos; 2022 May; 50(5):576-590. PubMed ID: 35153195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.
    Azanza JR; Mensa J; González Del Castillo J; Linares Rufo M; Molero JM; Madero Valle N; Barberán J
    Rev Esp Quimioter; 2022 Aug; 35(4):357-361. PubMed ID: 35822605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease.
    Mótyán JA; Mahdi M; Hoffka G; Tőzsér J
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
    Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
    Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™.
    Sathish JG; Bhatt S; DaSilva JK; Flynn D; Jenkinson S; Kalgutkar AS; Liu M; Manickam B; Pinkstaff J; Reagan WJ; Shirai N; Shoieb AM; Sirivelu M; Vispute S; Vitsky A; Walters K; Wisialowski TA; Updyke LW
    Int J Toxicol; 2022 Aug; 41(4):276-290. PubMed ID: 35603517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models.
    Cox RM; Lieber CM; Wolf JD; Karimi A; Lieberman NAP; Sticher ZM; Roychoudhury P; Andrews MK; Krueger RE; Natchus MG; Painter GR; Kolykhalov AA; Greninger AL; Plemper RK
    Nat Commun; 2023 Aug; 14(1):4731. PubMed ID: 37550333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 main protease inhibitors: What is moving in the field of peptides and peptidomimetics?
    Algar-Lizana S; Bonache MÁ; González-Muñiz R
    J Pept Sci; 2023 May; 29(5):e3467. PubMed ID: 36479966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paxlovid mouth likely is mediated by activation of the TAS2R1 bitter receptor by nirmatrelvir.
    Caronia L; Xi R; Margolskee RF; Jiang P
    Biochem Biophys Res Commun; 2023 Nov; 682():138-140. PubMed ID: 37806252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
    Atmar RL; Finch N
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
    Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
    BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir.
    Gerhart J; Cox DS; Singh RSP; Chan PLS; Rao R; Allen R; Shi H; Masters JC; Damle B
    Clin Pharmacokinet; 2024 Jan; 63(1):27-42. PubMed ID: 38177893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deuteration for Metabolic Stabilization of SARS-CoV-2 Inhibitors GC373 and Nirmatrelvir.
    Van Oers TJ; Piercey A; Belovodskiy A; Reiz B; Donnelly BL; Vuong W; Lemieux MJ; Nieman JA; Auclair K; Vederas JC
    Org Lett; 2023 Aug; 25(31):5885-5889. PubMed ID: 37523471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
    Greasley SE; Noell S; Plotnikova O; Ferre R; Liu W; Bolanos B; Fennell K; Nicki J; Craig T; Zhu Y; Stewart AE; Steppan CM
    J Biol Chem; 2022 Jun; 298(6):101972. PubMed ID: 35461811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A mathematical model of SARS-CoV-2 immunity predicts paxlovid rebound.
    Ranard BL; Chow CC; Megjhani M; Asgari S; Park S; Vodovotz Y
    J Med Virol; 2023 Jun; 95(6):e28854. PubMed ID: 37287404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
    Sutanto ST; Sinto R; Pasaribu A; Shakinah S
    Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS/MS in patients treated for COVID-19.
    Martens-Lobenhoffer J; Böger CR; Kielstein J; Bode-Böger SM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Dec; 1212():123510. PubMed ID: 36274268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurological side effects and drug interactions of antiviral compounds against SARS-CoV-2.
    Akhvlediani T; Bernard-Valnet R; Dias SP; Eikeland R; Pfausler B; Sellner J;
    Eur J Neurol; 2023 Dec; 30(12):3904-3912. PubMed ID: 37526048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.
    Lieber CM; Kang H-J; Sobolik EB; Sticher ZM; Ngo VL; Gewirtz AT; Kolykhalov AA; Natchus MG; Greninger AL; Suthar MS; Plemper RK
    J Virol; 2024 Sep; 98(9):e0090524. PubMed ID: 39207133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nirmatrelvir Plus Ritonavir: First Approval.
    Lamb YN
    Drugs; 2022 Apr; 82(5):585-591. PubMed ID: 35305258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.